Dave Singh1, Lisa Edwards, Ruth Tal-Singer, Stephen Rennard. 1. University of Manchester, Medicines Evaluation Unit, South Manchester University Hospitals Trust, Southmoor Road, Manchester M23 9QZ, UK. dsingh@meu.org.uk
Abstract
INTRODUCTION: The percentage of neutrophils in sputum are increased in COPD patients, and may therefore be a biomarker of airway inflammation. We studied the relationships between sputum neutrophils and FEV1, health status, exacerbation rates, systemic inflammation and emphysema, and long term variability at 1 year. METHODS: Sputum samples were obtained from 488 COPD patients within the ECLIPSE cohort. 359 samples were obtained at baseline, and 297 after 1 year. 168 subjects provided samples at both visits. Serum interleukin-6 (IL-6), IL-8, surfactant protein D and C-reactive protein levels were measured by immunoassays. Low-dose CT scans evaluated emphysema. RESULTS: Sputum neutrophil % increased with GOLD stage. There was a weak association between % sputum neutrophils and FEV1 % predicted (univariate r2 = 0.025 and 0.094 at baseline and year 1 respectively, p < 0.05 after multivariate regression). Similar weak but significant associations were observed between neutrophil % and health status measured using the St Georges Respiratory Questionairre. There were no associations between neutrophils and exacerbation rates or emphysema. Associations between sputum neutrophils and systemic biomarkers were non-significant or similarly weak. The mean change over 1 year in neutrophil % was an increase of 3.5%. CONCLUSIONS: Sputum neutrophil measurements in COPD are associated weakly with FEV1 % predicted and health status. Sputum neutrophil measurements were dissociated from exacerbation rates, emphysema and systemic inflammation.
INTRODUCTION: The percentage of neutrophils in sputum are increased in COPDpatients, and may therefore be a biomarker of airway inflammation. We studied the relationships between sputum neutrophils and FEV1, health status, exacerbation rates, systemic inflammation and emphysema, and long term variability at 1 year. METHODS: Sputum samples were obtained from 488 COPDpatients within the ECLIPSE cohort. 359 samples were obtained at baseline, and 297 after 1 year. 168 subjects provided samples at both visits. Serum interleukin-6 (IL-6), IL-8, surfactant protein D and C-reactive protein levels were measured by immunoassays. Low-dose CT scans evaluated emphysema. RESULTS: Sputum neutrophil % increased with GOLD stage. There was a weak association between % sputum neutrophils and FEV1 % predicted (univariate r2 = 0.025 and 0.094 at baseline and year 1 respectively, p < 0.05 after multivariate regression). Similar weak but significant associations were observed between neutrophil % and health status measured using the St Georges Respiratory Questionairre. There were no associations between neutrophils and exacerbation rates or emphysema. Associations between sputum neutrophils and systemic biomarkers were non-significant or similarly weak. The mean change over 1 year in neutrophil % was an increase of 3.5%. CONCLUSIONS: Sputum neutrophil measurements in COPD are associated weakly with FEV1 % predicted and health status. Sputum neutrophil measurements were dissociated from exacerbation rates, emphysema and systemic inflammation.
Authors: G Caramori; M Romagnoli; P Casolari; C Bellettato; G Casoni; P Boschetto; K F Chung; P J Barnes; I M Adcock; A Ciaccia; L M Fabbri; A Papi Journal: Thorax Date: 2003-04 Impact factor: 9.139
Authors: R A O'Donnell; C Peebles; J A Ward; A Daraker; G Angco; P Broberg; S Pierrou; J Lund; S T Holgate; D E Davies; D J Delany; S J Wilson; R Djukanovic Journal: Thorax Date: 2004-10 Impact factor: 9.139
Authors: Thérèse S Lapperre; Jiska B Snoeck-Stroband; Margot M E Gosman; Jan Stolk; Jaap K Sont; Désirée F Jansen; Huib A M Kerstjens; Dirkje S Postma; Peter J Sterk Journal: Am J Respir Crit Care Med Date: 2004-06-01 Impact factor: 21.405
Authors: James C Hogg; Fanny Chu; Soraya Utokaparch; Ryan Woods; W Mark Elliott; Liliana Buzatu; Ruben M Cherniack; Robert M Rogers; Frank C Sciurba; Harvey O Coxson; Peter D Paré Journal: N Engl J Med Date: 2004-06-24 Impact factor: 91.245
Authors: Dilyara G Yanbaeva; Mieke A Dentener; Martijn A Spruit; Jeanine J Houwing-Duistermaat; Daniel Kotz; Valéria Lima Passos; Emiel F M Wouters Journal: BMC Med Genet Date: 2009-03-09 Impact factor: 2.103
Authors: Jeong H Yun; Andrew Lamb; Robert Chase; Dave Singh; Margaret M Parker; Aabida Saferali; Jørgen Vestbo; Ruth Tal-Singer; Peter J Castaldi; Edwin K Silverman; Craig P Hersh Journal: J Allergy Clin Immunol Date: 2018-04-28 Impact factor: 10.793
Authors: Zhiqun Zhang; Stefania Mondello; Firas Kobeissy; Richard Rubenstein; Jackson Streeter; Ronald L Hayes; Kevin K W Wang Journal: Transl Stroke Res Date: 2011-12-07 Impact factor: 6.829
Authors: Matthew R Gingo; Jiayan He; Catherine Wittman; Carl Fuhrman; Joseph K Leader; Cathy Kessinger; Lorrie Lucht; William A Slivka; Yingze Zhang; Deborah K McMahon; Frank C Sciurba; Alison Morris Journal: Eur Respir J Date: 2013-02-21 Impact factor: 16.671